Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Lobaplatin crystal and preparation method and drug application thereof

A technology of lobaplatin and crystal, which is applied in new crystal form and its preparation method and in the application field of medicine, can solve the problems of poor stability and difficulty in making preparations, and achieve good stability, good fluidity and high solubility Effect

Active Publication Date: 2016-03-30
GUIZHOU YIBAI PHARMA CO LTD
View PDF3 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] The technical problem to be solved by the present invention is that in the past, lobaplatin anhydrate had deliquescence, was difficult to make preparations, and had poor stability.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Lobaplatin crystal and preparation method and drug application thereof
  • Lobaplatin crystal and preparation method and drug application thereof
  • Lobaplatin crystal and preparation method and drug application thereof

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0049] On the other hand, the present invention provides a method for preparing a new crystal form of lobaplatin that is simple to prepare, easy to operate, and suitable for scale-up production.

[0050] In a preferred embodiment, the preparation method of the new crystal form of lobaplatin of the present invention comprises the following steps:

[0051] a. Preparation of lobaplatin dihydrate: Weigh lobaplatin trihydrate in a container, add 15-30ml of organic solvent, suspend and stir at room temperature for 45-50h, filter, wash with ether, and obtain a white powder after vacuum drying, namely Lobaplatin dihydrate;

[0052] Wherein, the organic solvent is selected from methyl tert-butyl ether, toluene, diethyl ether, butyl acetate, 1,4-dioxane or n-heptane.

[0053] b. Preparation of the target crystal form: Weigh the lobaplatin dihydrate obtained in step a, put it in a container, add methanol or ethanol, stir at room temperature until the solid dissolves, filter off the inso...

Embodiment 1

[0058] Embodiment 1: Screening analysis of each crystal form

[0059] 1.1 Screening by room temperature volatile crystallization method

[0060] Take 20 mg of lobaplatin trihydrate sample and put it into a 10 ml sample bottle, add 3 ml of absolute ethanol or absolute methanol, after fully dissolving, place it in an environment of 25°C and slowly volatilize to obtain a dry solid, which is then determined by PXRD. The results are shown in Table 2 below:

[0061] Table 2 normal temperature volatilization and crystallization test results

[0062] Numbering

solvent

PXRD (possible crystal number)

1-1

Absolute ethanol

B

1-2

Anhydrous Methanol

B

[0063] The results showed that the crystal forms obtained in absolute methanol and absolute ethanol were compared and found to be the same crystal form, tentatively named as crystal form B.

[0064] 1.2 Screening by suspension crystallization method

[0065] Take 20mg of lobaplatin t...

Embodiment 2

[0107] Example 2: Preparation of a new crystal form of lobaplatin named Form F

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a lobaplatin crystal and a preparation method and drug application thereof, the lobaplatin crystal form is F, the melting point Tm. p. . is 229 + / -5 DEG C, diffraction peaks exist at the 2 theta angle values of 8.21, 11.60, 12.99, 15.24, 16.44, 17.11, 17.55, 18.42, 19.01, 19.20, 19.42, 21.81, 22.17, 22.42, 23.33, 23.85, 24.18, 24.40, 24.77, 25.46, 25.98, 26.13, 27.89, 28.42, 29.03, 30.32, 31.17, 31.94, 33.30, 36.20, 37.62 and 39.66 in an X-ray powder diffraction PXRD spectrum, wherein the 2 theta angle value error is in the range of 0.2. The crystal form F is obtained by adding methanol or ethanol into lobaplatin dihydrate, stirring at room temperature until the solid is dissolved, filtering insoluble matters out, adding dropwise slowly an organic solvent, after precipitation of a crystal, separating the crystal, and drying. Compared with lobaplatin and lobaplatin trihydrate in the prior art, the lobaplatin crystal in the crystal form F has better stability and solubility, is more suitable for the preparation of various forms of pharmaceutical preparations and storage and use, and can be better used to treat cancers such as breast cancer, small cell lung cancer or chronic granulocytic leukemia.

Description

technical field [0001] The invention relates to the field of medicines, in particular to a new crystal form of lobaplatin and its preparation method and application in medicines, belonging to the technical field of medicines. Background technique [0002] Lobaplatin (D19466), also known as Lobaplatin, is the third-generation platinum-based antineoplastic drug after cisplatin and carboplatin, and its chemical name is: cis-[trans-1,2-cyclobutane Alkanebis(methylamine)-N,N']-[(2S)-lactic acid-O1,O2]-platinum(II), the molecular formula is C 9 h 18 N 2 o 3 Pt, the molecular weight is 397.34, and the chemical structural formula is shown in the following formula (1): [0003] [0004] Lobaplatin has an alkylating effect and is an alkylating agent (broad sense). It has good anti-tumor effect, such as in vitro AH135-tumor, B16-melanoma, colon cancer 115, in vivo mouse P338 leukemia, etc. has a good inhibitory effect. Lobaplatin is characterized by strong anticancer activity,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07F15/00A61K31/282A61P35/00A61P35/02
Inventor 窦啟玲隋东虎张圣贵
Owner GUIZHOU YIBAI PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com